Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
Cong Wei,1,* Xiaoting Zhang,1,* Dan Liang,1 Jilong Yang,1 Jingwen Du,1 Chunyan Yue,1 Lan Deng1,2 1Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, People’s Republic of China; 2Department of Hematology, Shanghai Ninth People’s Hospital, Shan...
Guardado en:
Autores principales: | Wei C, Zhang X, Liang D, Yang J, Du J, Yue C, Deng L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/81cbb5af96724c7d935172592ed843c0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
por: HE Yundi, et al.
Publicado: (2021) -
CD4+ T cells in aged or thymectomized recipients of allogeneic stem cell transplantations
por: Takahashi,Hiroshi, et al.
Publicado: (2015) -
Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
por: Delaney Wolfe, et al.
Publicado: (2021) -
Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease
por: Aditya Rayasam, et al.
Publicado: (2021) -
Effect and mechanism of human umbilical cord mesenchymal stem cells on preventing murine acute graft-versus-host disease
por: HONG Tao, et al.
Publicado: (2021)